The Omaha-003 clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and have failed to respond to drugs or surgery to block the testes from making hormones, and after treatment with other drugs for prostate cancer. The Omaha-004 clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and whose […]
This year's Sons of Allen 11th Episcopal District AME Retreat will be held in Bartow, Florida, on May 21st - May 23rd. PHEN Ambassadors Mr. Barney Morris and Mr. Tony Hill, along with Rev. Adrian Backus, Director of Church Partnership and Community Outreach, will be presenting information about prostate cancer. Prostate cancer screenings will be […]
The EvoPAR Pro2 clinical trial is designed for men with high-risk prostate cancer linked to BRCA1 or BRCA2 gene changes who have completed radiation treatment and are currently receiving hormone therapy. Researchers are studying whether adding the investigational medication saruparib to standard treatment may help delay, slow down, or prevent the cancer from spreading to […]
This month, the focus is "Caring for the Caregiver: Emotional Well-being in Survivorship". For men living with prostate cancer, caregivers and family members are often the quiet strength behind the journey. They help coordinate appointments, support treatment decisions, communicate with healthcare providers, and manage the day-to-day needs of cancer care. But caregiving is more than […]
MEN — it’s time to prioritize YOUR health. Join us for the 2026 Men’s Health & Wellness Event — a day focused on health, education, resources, and community. Dr. Keith Crawford will present on prostate cancer. FREE Screenings provided by Lapcorp beginning at 9:00 am. FREE admission No insurance needed Open to the […]
IDeate-Prostate01 is a study comparing an investigational drug to docetaxel, which is a standard chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). IDeate-Prostate02 is a study, in which the investigational drug, is given alone or in combination with standard treatments for prostate cancer. This study is also trying to find a recommended dose of […]
🩵 Prostate Cancer Community Rally – Richmond, VA 🩵 📢 Attention Men Age 40+ — Especially Black Men, Who Face a Higher Risk for Prostate Cancer Join us for a free community event focused on prostate cancer awareness, education, and early detection. 📅 Saturday, June 20, 2026 🕘 9:00 AM – 1:30 PM 📍 Imani […]
💙 Father's Day Weekend: Protect Your Health. Protect Your Legacy. 💙 This Father's Day weekend, give yourself and your family one of the greatest gifts possible—your health. Join PHEN (Prostate Health Education Network), Ebenezer A.M.E. Church, Howard University Cancer Center, and community partners for a free Prostate Cancer Community Rally focused on education, awareness, and […]
What you will learn: Understand what ADT does and why testosterone matters Learn why monitoring testosterone before, during, and after therapy can support your survivorship planning Know what questions to ask your healthcare team about testosterone recovery Agenda: Understanding Testosterone Recovery: What ADT does, why recovery varies, and what the OPTYX Phase 4 Registry adds […]
The phase 2 LEGION‑100 study is evaluating an investigational treatment called SYNC‑T Therapy SV‑102 for men with mCRPC. SYNC‑T SV-102 therapy is an outpatient procedure that involves placing a needle-like […]
Moderated by Thomas Farrington, president and founder, PHEN The State of the Black Prostate Cancer Disparity Annual Address will provide an assessment of the progress, challenges, and opportunities impacting prostate […]
Moderated by Adrian Backus, JD, MDiv Eliminating prostate cancer disparities requires more than medical breakthroughs—it requires reaching Black men where they live, work, worship, learn, and gather. Over the years, PHEN and its partners have demonstrated the power of community-based engagement through churches, fraternities, community organizations, healthcare systems, and innovative public-private partnerships. Yet significant challenges […]